Search Results
Your search for The A,The A matches 32761 pages
Showing 29751 - 29800Lenalidomide Plus Rituximab Appears Promising as First-Line Therapy for Mantle Cell Lymphoma
Mantle cell lymphoma, which is characterized by CD5-positive, CD23-negative follicular mantle B cells with t(11:14)(q13;q32) translocation and cyclin D1 overexpression, is generally incurable and associated with a median survival of between 4 and 5 years. Although front-line treatment for mantle...
Study Shows Wide Variation in Costs to Treat Low-Risk Prostate Cancer
University of California, Los Angeles (UCLA) researchers have described costs across the entire care process for low-risk prostate cancer—from the time a patient checks in for his first appointment to his post-treatment follow-up testing—using time-driven activity-based costing. For the ...
Only 1 in 5 U.S. Patients With Pancreatic Cancer Gets Key Blood Test at Diagnosis
Only 1 in 5 patients with pancreatic cancer in the United States receives a widely available, inexpensive blood test at diagnosis that can help predict relative outcome (compared to others with the same disease stage) and guide treatment accordingly, a Mayo Clinic study showed. People who test...
Phase III Trials Fail to Show Noninferiority of Surgical Outcome for Laparoscopic vs Open Resection in Rectal Cancer
Two phase III trials, reported in JAMA by Fleshman et al and Stevenson et al, failed to show noninferiority of surgical outcome for laparoscopic vs open resection in patients with rectal cancer. ACOSOG Z6051 Trial In the American College of Surgeons Oncology Group (ACOSOG) Z6051 trial, reported...
No Reduction in Recurrent Colorectal Adenomas With Vitamin D and Calcium Supplementation
In a trial reported in The New England Journal of Medicine, Baron et al found that daily vitamin D and calcium supplementation did not reduce recurrence of colorectal adenomas in patients with recently diagnosed adenomas and no known polyps remaining after complete colonoscopy. Study Details In...
Breast Cancer Adjuvant Therapy Benefit Can Wax and Wane Over Time
After breast cancer surgery, women are prescribed adjuvant therapies such as chemotherapy and endocrine drugs to reduce the risk of the cancer returning. It has been assumed that the treatment effects of these therapies remain constant over time, but a new study from the Cancer Therapy &...
Antiangiogenic Breast Cancer Treatment May Benefit Only Patients With Well-Perfused Tumors
A Massachusetts General Hospital (MGH) research team, in collaboration with investigators at the Dana-Farber Cancer Institute, may have found a reason why the use of antiangiogenic drugs—which has improved outcomes for patients with several types of cancer—fails to benefit some breast...
No Significant Survival Improvement With Etirinotecan Pegol vs Physician’s Choice in Heavily Pretreated Advanced Breast Cancer
In the phase III BEACON trial reported in The Lancet Oncology, Perez et al found that etirinotecan pegol was not associated with a significant increase in overall survival compared with physician’s choice of treatment in women with locally recurrent or metastatic breast cancer previously...
6-Year Incidence of Cardiac Events in NCCTG N9831/Alliance Adjuvant Trastuzumab Trial
As reported in the Journal of Clinical Oncology by Advani et al, the cumulative incidence of cardiac events remained significantly higher at 6 years in breast cancer patients who received adjuvant trastuzumab (Herceptin) in the NCCTG N9831/Alliance trial. However, few new congestive heart failure...
Researchers Discover SEC23B, Gene Associated With Cowden Syndrome, Contributes to Thyroid Cancer Risk
Cleveland Clinic researchers have discovered a gene associated with Cowden syndrome, an inherited condition that carries high risks of thyroid, breast, and other cancers, and a subset of noninherited thyroid cancers. These findings were published by Yehia et al in the American Journal of Human...
Stool DNA Test Accurate in Screening for Colorectal Cancer in Alaska Native People
Cologuard stool DNA testing for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of the world's highest rates of colorectal cancer, concluded researchers from the Alaska Native Tribal Health Consortium and Mayo Clinic. The...
Chemoradiotherapy Survival Benefit in Elderly Patients With Limited-Stage SCLC
In a population-based study reported in the Journal of Clinical Oncology, Corso et al found that chemoradiotherapy was associated with an overall survival benefit vs chemotherapy in elderly patients with limited-stage small cell lung cancer (SCLC). Study Details The study involved National Cancer ...
American Cancer Society Report Finds Rising Rates of Breast Cancer Among African American Women, Especially in Southern States
Although white women have historically had higher incidence rates of breast cancer than African American women, a new report by the American Cancer Society (ACS) finds that, in 2012, the rates converged. The incidence rates were significantly higher in black women than in white women in seven...
Immunotherapy for Pancreatic Cancer Boosts Survival by More Than 75% in Preclinical Models
A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy—even when used without chemotherapy or radiation—can boost survival from pancreatic cancer by more than 75%. The findings are promising, and human clinical...
Exercise Could Provide a Margin of Safety for Women Who Want to Delay Preventive Mastectomy
Regular physical activity could play a role in helping women at high-risk of breast cancer delay the need for drastic preventive measures such as prophylactic mastectomy, according to new research led by the Perelman School of Medicine at the University of Pennsylvania. Results of the WISER Sister...
Study Identifies Splicing Alterations That Enable Resistance to CD19 CAR T-Cell Immunotherapy
Although the CD19 antigen expressed on most B-cell acute lymphoblastic leukemias (ALL) can be targeted with chimeric antigen receptor–armed T cells (CART-19), relapse rates among pediatric and adult patients with the cancer remain high. In this study by Sotillo et al, the researchers...
Reduced Relapse but No Quality-of-Life Benefit With ATRA/Arsenic Trioxide vs ATRA/Idarubicin in Acute Promyelocytic Leukemia
In a UK-based phase III trial (AML17) reported in The Lancet Oncology, Burnett et al found that a chemotherapy-free regimen of arsenic trioxide plus all-trans retinoic acid (ATRA) did not improve quality of life, the primary endpoint, vs ATRA plus idarubicin in patients with acute promyelocytic...
29-Year Single-Center Longitudinal Experience Indicates 2% Annual Risk of Breast Cancer in Lobular Carcinoma in Situ
As reported by King et al in the Journal of Clinical Oncology, 29-year longitudinal experience at Memorial Sloan Kettering Cancer Center indicates an annual 2% risk of breast cancer in women with lobular carcinoma in situ. Risk was reduced with chemoprevention. Study Details The study involved...
FDA Approves Adjuvant Ipilimumab to Reduce the Risk of Melanoma Returning After Surgery
The U.S. Food and Drug Administration has expanded the approved use of ipilimumab (Yervoy) to include a new use as adjuvant therapy for patients who have cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm and have undergone complete resection, including total...
Telotristat Etiprate Shows Clinical Benefit in Treating Carcinoid Syndrome in Cancer Patients When Added to Standard of Care
Lexicon Pharmaceuticals, Inc's telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study presented...
Newly Discovered Tumor-Suppressor Gene Affects Melanoma Survival
Of the hundreds of genes that can be mutated in a single case of melanoma, only a handful may be true drivers of cancer. A new study published by Arafeh et al in Nature Genetics, a Weizmann Institute of Science team has revealed one of the drivers of a particularly deadly subset of melanomas that...
FDA Approves Talimogene Laherparepvec for Unresectable Recurrent Melanoma
The U.S. Food and Drug Administration (FDA) has approved the biologics license application for talimogene laherparepvec (Imlygic), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma...
Second-Line Lenvatinib Plus Everolimus Improves Progression-Free Survival vs Everolimus in Metastatic Renal Cell Carcinoma in Phase II Trial
In a phase II trial reported in The Lancet Oncology, Motzer et al found that the combination of the multi–tyrosine kinase inhibitor lenvatinib (Lenvima) plus the mTOR inhibitor everolimus (Afinitor) significantly improved progression-free survival vs everolimus alone in patients with...
Parabens May Increase Breast Cancer Risk at Lower Doses Than Previously Thought
Estrogen-mimicking chemicals called parabens, which are commonly found in an array of personal care products, may be more dangerous at lower doses than previously thought, according to a new study. The findings, published by Pan et al in Environmental Health Perspectives, could have implications...
Study Finds Tumor-Derived Exosomes May Predict Patients Likely to Develop Cancer Metastasis
Researchers investigating the role of exosomes, comprised of tumor-derived proteins, in the development of cancer metastasis have found that an “exosomal protein signature” could identify patients at risk for metastasis. The research also indicates that integrin expression profiles of...
Good Outcome With Neoadjuvant Chemoradiation and Local Excision in Clinical T2,N0 Distal Rectal Cancer
In a multi-institutional phase II trial (ACOSOG Z6041) reported in The Lancet Oncology, Garcia-Aguilar et al found that neoadjuvant chemoradiotherapy and local excision was associated with an acceptable disease-free survival rate, albeit not so high as anticipated, in patients with clinical stage...
ASCO Calls for Comprehensive Payment Reform to Address Issue of Site Neutrality
ASCO has called for comprehensive physician payment reform to support the full scope of services required by patients with cancer, rather than jeopardizing patient outcomes by reducing the available resources in a particular cancer care setting in an effort to achieve "site neutrality" in...
National Coalition for Cancer Survivorship Honors Richard Pazdur, MD, and Ellen Goodman
On October 21 in Washington, DC, the National Coalition for Cancer Survivorship (NCCS) hosted a reception to honor Richard Pazdur, MD, and Ellen Goodman. Special guest Robert M. Califf, MD, Deputy Commissioner for Medical Products and Tobacco at the U.S. Food and Drug Administration (FDA),...
A Cancer Diagnosis Can Lead to Significant Loss of Working Hours, Income
A new analysis indicates that when American adults are diagnosed with cancer, they experience significant decreases in the probability of working, in the number of hours they work, and correspondingly, in their incomes. Such negative impacts of a cancer diagnosis are particularly pronounced among...
ASTRO 2015: The Addition of 24 Months of Daily Antiandrogen Therapy Improves Overall Survival Following Recurrence After a Radical Prostatectomy
Prostate cancer patients who face recurrence after radical prostatectomy have better overall survival rates with a combination of salvage radiation therapy and 24 months of antiandrogen therapy than with radiation therapy alone, according to research (Abstract LBA5) presented by Shipley et al on...
ASTRO 2015: A Shorter Radiation Therapy Schedule Can Be as Effective as a Conventional Schedule for Men With Low-Risk Prostate Cancer
Hypofractionated radiation therapy results in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research (Abstract LBA6) presented by Lee et al October 19, 2015, at the American Society for Radiation Oncology...
ASTRO 2015: Genomic Classifier Appears to Predict Metastasis in Patients With Prostate Cancer Following Prostatectomy
For men with prostate cancer who have had a prostatectomy and salvage radiation therapy, analyzing their tumor genome provides clues as to whether their cancer will metastasize, thereby enabling clinicians to better personalize treatment options, according to research presented by Den et al...
ASTRO 2015: Pediatric Patients With Ependymoma Have Favorable Outcomes With Immediate Postsurgical Radiation Therapy
Outcomes for pediatric patients as young as 12 months old with ependymoma who are treated with immediate postoperative radiation therapy are favorable and consistent, based upon tumor surgical resection and tumor grade, according to research presented by Merchant et al (Abstract 1) on October...
Addition of Cediranib to Carboplatin/Paclitaxel Improves Progression-Free Survival in Metastatic/Recurrent Cervical Cancer in UK Phase II Trial
In a UK phase II trial reported in The Lancet Oncology, Symonds et al found that the addition of the investigational VEGFR1, -2, and -3 inhibitor cediranib to carboplatin/paclitaxel improved progression-free survival in patients with metastatic or relapsed cervical cancer. The addition of cediranib ...
FDA Approves Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
The U.S. Food and Drug Administration today approved the chemotherapy drug trabectedin (Yondelis) for the treatment of specific soft-tissue sarcomas—liposarcoma and leiomyosarcoma—that are unresectable or metastatic. This treatment is approved for patients who previously received...
Risk-Based Approach to Guide Surveillance After Resection for Renal Cell Carcinoma
As reported in the Journal of Clinical Oncology, Stewart-Merrill et al at Mayo Clinic, Rochester, have developed an approach to determining surveillance duration that attempts to balance risk of recurrence vs risk of non–renal cell carcinoma death after resection for renal cell carcinoma....
Statement From AACR CEO Margaret Foti, PhD, MD (hc), on Vice President Biden’s Call for More Cancer Research
Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), issued the following statement regarding Vice President Joe Biden’s call for a “moon shot” to end cancer: “We extend our deepest sympathy to Vice President Biden and his family for the...
ASTRO 2015: Hypofractionated Radiation Therapy May Be an Acceptable Treatment for Some Patients With Localized Prostate Cancer
Long-term patient-reported outcomes indicate that for some men with localized prostate cancer, hypofractionated intensity-modulated radiation therapy (IMRT) may be a reasonable treatment option and result in similar quality-of-life outcomes, compared to conventional radiation therapy, according to...
ASTRO 2015: Patients With Intermediate-Risk Meningiomas Who Receive Postoperative Radiotherapy Have a 96% 3-Year Progression-Free Survival
Patients with intermediate meningiomas treated with radiation therapy after surgery experienced a 96% 3-year progression-free survival rate and had minimal adverse events, according to research presented by Rogers et al October 21, 2015, at the American Society for Radiation Oncology’s...
ASTRO 2015: Androgen-Deprivation Therapy for 2 Years After Radiotherapy Improves Disease-Free Survival in Patients With Advanced Prostate Cancer
A long-term follow-up of RTOG 9202 indicated that for patients with locally advanced prostate cancer, an additional 24 months of long-term androgen-deprivation therapy after radiation therapy plus short-term androgen-deprivation therapy improved disease-free survival by 60%, compared to patients...
ASTRO 2015: Involved-Field Irradiation for Locally Advanced Esophageal Cancer Reduces Toxicity Without Increasing Locoregional Lymph Node Recurrence
For patients with locally advanced esophageal cancer that has spread to the lymph nodes, radiation therapy that targets only the involved lymph node regions results in less toxicity without causing a statistically significant difference in locoregional lymph node recurrence, distant failure, and...
FDA Approves Liposomal Irinotecan for Advanced Pancreatic Cancer
The U.S. Food and Drug Administration today approved irinotecan liposome injection (Onivyde), in combination with fluorouracil (5-FU) and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. According to the National...
NCCN Unveils Evidence Blocks for CML and Multiple Myeloma
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 26 of the world's leading cancer centers, has unveiled its new value initiative—the NCCN Evidence Blocks, published within new versions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for...
ASTRO 2015: Intensity-Modulated Radiotherapy Causes Less Inflammation Than 3D Conformal Radiotherapy in Lung Cancer Patients
Patients with stage III non–small cell lung cancer (NSCLC) who receive intensity-modulated radiation therapy (IMRT) have 44% fewer cases of severe pneumonitis and improved likelihood of completing consolidative chemotherapy after radiation, compared to patients who receive three-dimensional...
ASTRO 2015: Coordinated Radiation Therapy and Palliative Care Based on Patient Feedback Lead to Better Quality of Life, Reduced Health-Care Costs
A collaborative, patient-reported outcome–based approach by palliative care and radiation oncology teams results in better outpatient symptom management and a decrease in end-of-life hospitalizations and costs for late-stage cancer patients, according to research presented by Read et al...
ASTRO 2015: Image-Guided Intensity-Modulated Radiation Therapy Reduces Bowel Side Effects in Cervical Cancer Patients
For cervical cancer patients undergoing postsurgical radiation therapy, image-guided intensity-modulated radiation therapy (IMRT) resulted in a 14% reduction in moderate-to-severe bowel side effects when compared to conventional three-dimensional conformal radiation therapy (3D CRT), according to...
ASTRO 2015: Frequent Post-Treatment Follow-up by Advance Practice Nurses Improves Care for Patients With High-Risk Head and Neck Cancer
For high-risk patients who receive chemoradiotherapy for head and neck cancer, frequent follow-up appointments conducted by advance practice nurses (APNs) in a clinical outpatient setting allowed for more intensive symptom management, resulting in fewer post-treatment emergency room visits and...
How Physicians Communicate With Parents May Discourage HPV Vaccination of Adolescents
A nationwide online survey of 776 pediatricians and family physicians assessing the quality of their human papillomavirus (HPV) vaccine recommendations to parents has found that a sizable minority of physicians—27%—said they do not strongly endorse HPV vaccination, and 26% and 39%...
Study Compares Maintenance Strategies After First-Line Oxaliplatin/Fluoropyrimidine/Bevacizumab in Patients With Metastatic Colorectal Cancer
In a German noninferiority phase III trial (AIO 0207) reported in The Lancet Oncology, Hegewisch-Becker et al found that maintenance treatment with bevacizumab (Avastin) was noninferior to a fluoropyrimidine plus bevacizumab in time to maintenance strategy failure following first-line treatment...
American Cancer Society Updates Its Breast Cancer Screening Guidelines for Average-Risk Women
After commissioning a systematic evidence review of the breast cancer screening literature to inform an update of its 2003 breast cancer screening interval guideline, the American Cancer Society (ACS) released new guidelines for women at average risk of breast cancer. The recommendations include...
